<?xml version='1.0' encoding='utf-8'?>
<document id="22577882"><sentence text="Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms."><entity charOffset="71-82" id="DDI-PubMed.22577882.s1.e0" text="artemisinin" /><entity charOffset="117-127" id="DDI-PubMed.22577882.s1.e1" text="androstane" /><pair ddi="false" e1="DDI-PubMed.22577882.s1.e0" e2="DDI-PubMed.22577882.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22577882.s1.e0" e2="DDI-PubMed.22577882.s1.e1" /></sentence><sentence text="Widespread resistance to antimalarial drugs requires combination therapies with increasing risk of pharmacokinetic drug-drug interactions" /><sentence text=" Here, we explore the capacity of antimalarial drugs to induce drug metabolism via activation of constitutive androstane receptors (CAR) by ligand binding"><entity charOffset="110-120" id="DDI-PubMed.22577882.s3.e0" text="androstane" /></sentence><sentence text="" /><sentence text="A total of 21 selected antimalarials and 11 major metabolites were screened for binding to CAR isoforms using cellular and in vitro CAR-coactivator interaction assays, combined with in silico molecular docking" /><sentence text=" Identified ligands were further characterized by cell-based assays and primary human hepatocytes were used to elucidate induction of gene expression" /><sentence text="" /><sentence text="Only two artemisinin derivatives arteether and artemether, the metabolite deoxyartemisinin and artemisinin itself demonstrated agonist binding to the major isoforms CAR1 and CAR3, while arteether and artemether were also inverse agonists of CAR2"><entity charOffset="9-20" id="DDI-PubMed.22577882.s8.e0" text="artemisinin" /><entity charOffset="47-57" id="DDI-PubMed.22577882.s8.e1" text="artemether" /><entity charOffset="74-90" id="DDI-PubMed.22577882.s8.e2" text="deoxyartemisinin" /><entity charOffset="95-106" id="DDI-PubMed.22577882.s8.e3" text="artemisinin" /><pair ddi="false" e1="DDI-PubMed.22577882.s8.e0" e2="DDI-PubMed.22577882.s8.e0" /><pair ddi="false" e1="DDI-PubMed.22577882.s8.e0" e2="DDI-PubMed.22577882.s8.e1" /><pair ddi="false" e1="DDI-PubMed.22577882.s8.e0" e2="DDI-PubMed.22577882.s8.e2" /><pair ddi="false" e1="DDI-PubMed.22577882.s8.e0" e2="DDI-PubMed.22577882.s8.e3" /><pair ddi="false" e1="DDI-PubMed.22577882.s8.e1" e2="DDI-PubMed.22577882.s8.e1" /><pair ddi="false" e1="DDI-PubMed.22577882.s8.e1" e2="DDI-PubMed.22577882.s8.e2" /><pair ddi="false" e1="DDI-PubMed.22577882.s8.e1" e2="DDI-PubMed.22577882.s8.e3" /><pair ddi="false" e1="DDI-PubMed.22577882.s8.e2" e2="DDI-PubMed.22577882.s8.e2" /><pair ddi="false" e1="DDI-PubMed.22577882.s8.e2" e2="DDI-PubMed.22577882.s8.e3" /></sentence><sentence text=" Dihydroartemisinin and artesunate acted as weak inverse agonists of CAR1"><entity charOffset="1-19" id="DDI-PubMed.22577882.s9.e0" text="Dihydroartemisinin" /><entity charOffset="24-34" id="DDI-PubMed.22577882.s9.e1" text="artesunate" /><pair ddi="false" e1="DDI-PubMed.22577882.s9.e0" e2="DDI-PubMed.22577882.s9.e0" /><pair ddi="false" e1="DDI-PubMed.22577882.s9.e0" e2="DDI-PubMed.22577882.s9.e1" /></sentence><sentence text=" While arteether showed the highest activities in vitro, it was less active than artemisinin in inducing hepatic CYP3A4 gene expression in hepatocytes"><entity charOffset="81-92" id="DDI-PubMed.22577882.s10.e0" text="artemisinin" /></sentence><sentence text="" /><sentence text="Artemisinin derivatives and metabolites differentially affect the activities of CAR isoforms and of the pregnane X receptor (PXR)"><entity charOffset="0-11" id="DDI-PubMed.22577882.s12.e0" text="Artemisinin" /></sentence><sentence text=" This negates a common effect of these drugs on CAR/PXR-dependent induction of drug metabolism and further provides an explanation for artemisinin consistently inducing cytochrome P450 genes in vivo, whereas arteether and artemether do not"><entity charOffset="135-146" id="DDI-PubMed.22577882.s13.e0" text="artemisinin" /></sentence><sentence text=" All these drugs are metabolized very rapidly, but only artemisinin is converted to an enzyme-inducing metabolite"><entity charOffset="56-67" id="DDI-PubMed.22577882.s14.e0" text="artemisinin" /></sentence><sentence text=" For better understanding of pharmacokinetic drug-drug interaction possibilities, the inducing properties of artemisinin metabolites should be considered"><entity charOffset="109-120" id="DDI-PubMed.22577882.s15.e0" text="artemisinin" /></sentence><sentence text="" /></document>